Fennec Pharmaceuticals (FENC) Total Liabilities (2010 - 2026)

Fennec Pharmaceuticals (FENC) has 16 years of Total Liabilities data on file, last reported at $35.1 million in Q4 2025.

• Quarterly Total Liabilities fell 30.97% year-over-year to $35.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $35.1 million (down 30.97% YoY) and the FY2025 annual result came in at $35.1 million, down 30.97% from the prior year.
• Total Liabilities slipped to $35.1 million in Q4 2025, from $53.8 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $66.2 million in Q1 2024 to a low of $5.8 million in Q2 2021.
• A 5-year average of $34.2 million and a median of $29.5 million in 2022 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2021 — Total Liabilities sank 85.16% — and 2022, when it jumped 344.26%.
• Tracing FENC's Total Liabilities over 5 years: stood at $6.6 million in 2021, then surged by 344.26% to $29.5 million in 2022, then surged by 30.43% to $38.5 million in 2023, then jumped by 32.04% to $50.8 million in 2024, then tumbled by 30.97% to $35.1 million in 2025.
• The last three Total Liabilities figures came in at $35.1 million (Q4 2025), $53.8 million (Q3 2025), and $52.3 million (Q2 2025), per Business Quant data.